Analysts at Credit Suisse have upgraded this pharmaceutical company’s shares to an outperform rating from neutral with an increased price target of $1.00. The broker has made the move after assessing the market opportunity for two news products Mayne Pharma plans to release this year. Furthermore, the broker has suggested that investors view any earnings season share price weakness as a buying opportunity.
- Forums
- ASX - By Stock
- Can MYX become Blackmores of generics
Analysts at Credit Suisse have upgraded this pharmaceutical...
-
- There are more pages in this discussion • 121 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
Add MYX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$4.03 |
Change
-0.190(4.50%) |
Mkt cap ! $342.8M |
Open | High | Low | Value | Volume |
$4.10 | $4.22 | $4.02 | $1.235M | 303.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2500 | $4.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.04 | 164 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2500 | 4.020 |
3 | 6375 | 4.010 |
9 | 17920 | 4.000 |
1 | 164 | 3.990 |
3 | 1415 | 3.980 |
Price($) | Vol. | No. |
---|---|---|
4.040 | 164 | 1 |
4.050 | 164 | 1 |
4.060 | 164 | 1 |
4.070 | 164 | 1 |
4.080 | 164 | 1 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |